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Review Article
PATHOLOGICAL CHARACTERISTICS OF 
CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL 
LYMPHOCYTIC LYMPHOMA
Chronic lymphocytic leukemia/small lymphocytic lym-
phoma (CLL/SLL) usually exhibits heterogeneous features 
such as ill-defined bright nodules, termed proliferation cen-
ters, with chromatin-rich background cells (Figure 1).   The 
proliferation centers are composed of paraimmunoblasts, 
which are medium-sized cells, and the Ki67 index of these 
cells is higher than that of ordinary CLL/SLL cells.   On the 
contrary, the majority of CLL/SLL cells are usually “small” 
lymphoma cells, but they are slightly larger than normal lym-
phocytes (Figure 2).   In some cases, paraimmunoblasts are 
prominent and such cases should be differentiated from fol-
licular lymphomas.   By lymphoma-cell morphology and 
immunostaining, this differential diagnosis is simple.   CLL/
SLL cases may exhibit prominent paraimmunoblasts (Figure 
3).   Such cases should not be diagnosed as Richter syndrome 
because it features large blast cells; one feature of diffuse 
large B-cell lymphoma is the monotonous proliferation of 
large cells (the nucleus is more than twice the size of that of 
normal lymphocytes with varying cytoplasm sizes) (Figure 
4).
Bone marrow biopsy demonstrates many features.   Some 
cases exhibit a nodular pattern of infiltration, or interstitial or 
mixed nodular and interstitial pattern, whereas others have 
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such cases are often disseminated.   Lymphoplasmacytic lymphoma should also be a differential diagnosis for CLL/SLL.   It 
frequently demonstrates MYD88 L265P, which is a key differential finding.   By immunohistological examination, the expres-
sion of lymphoid enhancer-binding factor 1 is specific for CLL/SLL and can be a good marker in the differential diagnosis.
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Fig. 1. Typical features of CLL/SLL. There are two 
proliferation centers in this field. If the proliferation 
centers are prominent, follicular lymphoma is to be 
differentiated.
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diffuse involvement, which usually suggests more advanced 
disease.1
Immunohistologically, circulating leukemic B cells 
express CD19, and weak surface CD20, CD22, and CD79b. 
They are positive for CD5, and CD43, and strongly positive 
for CD23 and CD200.   They are negative for CD10, FMC7 
(usually), and cyclinD1, although cyclinD1 may be positive 
at proliferation centers.1   Lymphoid enhancer-binding factor 
1 (LEF1) is specific to CLL/SLL and is a good marker in the 
differential diagnosis.   Menter T et al. reported that 77/80 of 
CLL cases were positive for LEF1 (Figure 5), whereas only 
one of 38 follicular lymphoma and two of 33 marginal zone 
B-cell lymphoma cases were positive.   The sensitivity of 
LEF1 for CLL is 0.96 and the specificity is 0.93.2 O’Malley 
DP et al. reported that only 4-9% of MCL cases express 
LEF1.3   The differential diagnosis by immunostaining and 
flow cytometry analysis is summarized in Table 1.
Although CLL/SLL has no specific genetic markers, most 
(80-90%) cases have cytogenetic abnormalities.   The most 
common alternations are deletions in 13q14.3 and trisomy 12 
or partial trisomy 12q13.   Deletion in 11q22-23, 17q13, or 
6q21 are less common.   Deletion in 11q (ATM and BIRC3) 
and 17p (TP53) leads to a poorer clinical outcome, whereas 
isolated deletion in 13q14 is associated with a more favorable 
clinical course.1
CLL, SLL, AND MONOCLONAL B-CELL 
LYMPHOCYTOSIS
In the 2017 WHO classification,1 monoclonal B-cell lym-
phocytosis (MBL) is defined as a monoclonal B-cell count 
less than 5X109/L in peripheral blood of subjects who have 
no associated lymphadenopathy, organomegaly, or other 
extramedullary involvement.   MBL is classified into three 
categories: (1) CLL-type, (2) atypical CLL type, and (3) non-
CLL type.   The CLL type is the most common (75% of all 
cases), and it is characterized by B-cell markers (CD19, 
CD20 (weak)), CD23, and CD5, and the B-cells exhibit light 
chain restriction or lack surface immunoglobulin.   The esti-
mated incidence of CLL-type MBL is 3.5% to 12% in 
healthy individuals.   Although all CLLs are preceded by 
MBL, low-count (lower than 0.5X109L) MBL does not prog-
ress to CLL, whereas high-count (0.5X109L or higher) MBL 
has features identical to low-stage CLL and progresses to 
therapy-required CLL at a rate of 1-2%/year.   MBL cells 
usually have mutated IGHV genes.
MBL has an atypical CLL phenotype positive for CD19, 
CD20 (bright), CD5, and surface immunoglobulin.   CD23 
Fig. 2. “Small-cell” component of CLL/SLL. In com-
parison with non-neoplastic lymphocytes (arrows), 
lymphoma cells are slightly larger than “true” non-
neoplastic small lymphocytes.
Fig. 3. Paraimmunoblasts. These cells have a promi-
nent nucleoli, and are approximately 1.5-times larger 
than non-neoplastic lymphocytes.
Fig. 4. Richter’s syndrome. The proliferated cells 
have a large nucleus that is more than twice the size of 
that of small lymphocytes.
Fig. 5. LEF1 expression in CLL/SLL. The lymphoma 
cells are highly positive for LEF1.
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may be negative, and such cases should be carefully excluded 
from those of mantle cell lymphoma and other B-cell lym-
phomas.   MBL with a non-CLL phenotype is characterized 
by negative or weak CD5 expression, and CD19 and CD20-
positive B-cells.   Some cases exhibit transient clonal expan-
sion and are self-limited.   Additional phenotypic and cytoge-
netic studies are needed to exclude a specific lymphoid 
neoplasm.
SLL includes cases with a circulating CLL cell count of 
less than 5X109/L and documented nodal, splenic, or other 
extramedullary involvement.   SLL should be differentiated 
from CLL-type MBL.   Nodal infiltration by CLL-type cells 
without notable proliferation centers in individuals without 
lymphoadenopathy (more than 1.5 cm across) may constitute 
a nodal equivalent of MBL rather than SLL.1
DIFFERENTIAL DIAGNOSIS: MANTLE CELL 
LYMPHOMA
Mantle cell lymphoma (MCL) is also positive for CD5. 
Most mantle cell lymphomas are composed of intermediate 
lymphocytes and centrocytes exhibiting irregular nuclear 
contours, which is an important differential point (Figure 6). 
However, it may be composed of small-sized cells (Figure 7) 
that resemble CLL/SLL.   Saksena A et al.4 reported that 103 
(13%) MCL cases were weakly positive for CD23.   CD23 
expression in CLL/SLL is usually high.   CD23-positive 
MCL lymphoma has an increased leukocyte count, bone mar-
row involvement, and leukemic presentation.   Of note, 
CD23-positive MCL is more often associated with CD200 
positivity and weak SOX11 expression.   Although patients 
with CD23-positive MCL have a leukemic presentation simi-
lar to CLL, their prognosis is better than that of CD23-
negative patients.   The expression of CD23 is closely associ-
ated with CD200 expression.   Ye H et al.5 reported similar 
findings and referred to such cases as smoldering mantle cell 
lymphoma.   CD200 is an important marker of CLL/SLL in 
the differential diagnosis from other CD5-positive indolent 
lymphomas.   However, Hu Z et al.6 reported that approxi-
mately 4% of MCL (25 cases in their series) is positive for 
CD200, and most of these cases (76%) are positive for CD23. 
Moreover, only 24% of CD200-positive MCL cases express 
SOX11, 39% (9 cases) exhibit round nuclear contours, simi-
lar to CLL, and 44% of (11 cases) cases are a non-nodal leu-
kemic variant of MCL, which is closely related to IGHV-
mutated cases.   CLL/SLL can be subdivided into two 
groups: IGHV-unmutated and IGHV-mutated, and the patient 
prognosis of the former group is poorer than that of the latter 
group.   Of MCL cases, only a small subset is IGHV-mutated, 
which is frequently associated with a non-nodal leukemic 
presentation.   In conclusion, CD200-positive MCL is highly 
similar to CLL/SLL, and IgH-cylinD1 rearrangement is 
needed for the differential diagnosis.
CD200 belongs to a type I immunoglobulin gene 
Fig. 7. Mantle cell lymphoma. This case is composed 
of lymphoma cells, which are almost the same size as 
small lymphocytes, and was difficult to distinguish 
from small lymphocytic lymphoma without immuno-
histological examination.
CD19 CD20 CD22 CD79b CD5 CD10 CD23 CD200 cyclinD1 BCL2 LEF1 IRTA1
CLL/SLL + +weak +weak +weak + - +strong +strong - + + -
Mantle cell lymphoma + + + + + - - - + + - -
Follicular lymphoma + + + + - + - - - ++ - -
Marginal zone B-cell lymphoma + + + + - - - - - + - +
Lymphoplasmacytic lymphoma + + + + - - - - - + - -
Table 1. Immunophenotype of indolent lymphomas, including mantle cell lymphoma*
*: The presented immunophenotype of each lymphoma is the most common. There are rare exceptional findings, which are described in the 
text.
Fig. 6. Mantle cell lymphoma with typical features. 
The lymphoma cells are intermediate between small 
lymphocytes and medium-sized centrocytes with irreg-
ular nuclei contours.
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superfamily composed of a light-chain-like structure with 
extracellular variable and constant-like domains, and a cyto-
plasmic tail.   CD23 is also an important marker of CLL/
SLL.   It is a low-affinity IgE receptor, and contains a 
C-terminal lectin-like domain, which resembles C-type car-
bohydrate-recognition domains.7   CD23 has two isotypes, 
CD23a and CD23b.8   As described above, some MCL cases 
express low-level CD23, which is closely related to the 
expression of CD200.   To our knowledge, the relationship 
between CD200 and CD23 has not been clarified.
OTHER CD5-POSITIVE LYMPHOMAS
CD5 is another important marker of CLL/SLL.   CD5 
was first found in mice, and CD5-positive B-cells (B-1 cells) 
are distinct from CD5-negative B-cells (B-2 cells).9   B-1 
cells are responsible for natural antibody production and 
rapid immune responses.   B-1 cells in humans are abundant 
in cord blood and the fetal spleen.   CLL is thought to origi-
nate from B-1 cells.   Of note, CLL is characterized not only 
by CD5 expression, but also by an abnormal BCR repertoire 
encoding autoreactive and/or poly-reactive antibodies. 
Indeed, an increase in CD5-positive cells is observed in 
patients with autoimmune diseases.   B-1 cells may prolifer-
ate greatly with age and eventually develop into CLL.9
As described above, CD5 is usually observed in CLL and 
MCL, and the incidence of CLL and MCL in Japan is 1% and 
2%, respectively.   Their incidences in Western countries are 
higher, accounting for 6% of all lymphomas.   This strongly 
suggests that Japanese (and Asian) people infrequently 
develop B-1 cell-related lymphomas.
Marginal zone B-cell lymphoma (MZL) is composed of 
mucosa-associated lymphoid tissue (MALT) lymphoma, 
nodal MZL, and splenic MZL.   CD5 is rarely positive in 
MALT lymphoma.   Jaso J et al.10 described 14 cases of CD5-
positive MALT lymphoma: 4 in the salivary glands, 2 in the 
nasopharynx, 1 each in the conjunctiva, thyroid gland, stom-
ach, colon, skin, lung, kidney, and retroperitoneum. 
Approximately 60% of MALT lymphoma cases originate 
from the stomach, but CD5-positive MALT lymphoma is rare 
in the stomach, making CD5-positive cases rare.   CD5-
positive MALT lymphoma was reported to commonly pres-
ent with disseminated disease, although the prognosis is fair.
MALT lymphoma may comprise small lymphoma cells 
such as ocular adnexal MALT lymphoma (Figure 8) and gas-
tric MALT lymphoma with t(11;18) (Figure 9).
Jaso JM et al.11 compared 7 patients with CD5-positive 
nodal MZL with 66 with CD5-negative nodal MZL.   Six of 7 
CD5-positive nodal MZL patients exhibited wide-spread 
lymphoadenopathy and bone marrow involvement.   They 
concluded that CD5-positive nodal MZL often presents dis-
semination, but the patients have an indolent clinical course.
Kojima M et al.12 reported 11 patients with CD5-positive 
splenic MZL with leukemic manifestation.   They found that 
less than 20% of splenic MZL patients are CD5 positive. 
The clinical characteristics of the examined patients did not 
differ from those of CD5-negative patients.   IRTA-1 is spe-
cific for marginal zone B-cell lymphoma and is useful for 
diagnosis.13
Li Y et al.14 reported 88 patients with CD5-positive follic-
ular lymphoma.   For MZL, CD5-positive patients often 
exhibit dissemination, bone marrow involvement, and/or leu-
kemic state.   In contrast, patients with CD5-positive follicu-
lar lymphoma more commonly have a high international 
prognostic index, often develop diffuse large B-cell lym-
phoma, and have a shorter median progression-free survival. 
These findings suggest that CD5 expression in follicular lym-
phoma is closely related to aggressiveness, and the role of 
CD5 varies among lymphomas.
LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Lymphoplasmacytic lymphoma is closely associated with 
Waldenstrom macroglobulinemia.   It is composed of small 
lymphomacytes intermingled with plasmacytic cells (Figures 
10 and 11).   The typical morphology is not difficult to differ-
entiate from that of CLL/SLL; however, some cases demon-
strate lymphoplasmacytoid features of a small nucleus with 
heterochromatin in a characteristic cartwheel or clock face 
arrangement and narrow cytoplasm with occasional Dutcher 
Fig. 9. Gastric MALT lymphoma with t(11;18). The 
lymphoma cells are uniform, and nuclear size is simi-
lar to that in SLL.
Fig. 8. Ocular-adnexal MALT lymphoma. Lymphoma 
cells are uniform and similar to those in SLL.
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bodies (Figure 12).   Such cases resemble CLL/SLL. 
Lymphoplasmacytic lymphoma is highly positive for CD5, 
but not CD23.   The most important characteristic of lympho-
plasmacytic (including lymphoplasmacytoid) lymphoma is 
MYD88 mutation.15   Lymphoplasmacytic lymphoma involv-
ing extranodal organs is often difficult to differentiate from 
MALT lymphoma.   Both lymphoma types are associated 
with plasma cells with Dutcher bodies.   Treon SP et al. 
reported that most (approximately 90%) LPL cases have 
MYD88 L265P.15   Similar reports have been published, and 
although examination of MYD88 mutation is useful to diag-
nose LPL, MYD88 L265P is  not  specif ic  to LPL. 16 
Approximately 10% of marginal zone B-cell lymphomas 
exhibit this mutation.   CLL/SLL also has this mutation, 
although rarely.   Regarding diffuse large B-cell lymphoma 
(DLBCL), CNS, testicular, and leg-type lymphomas highly 
frequently exhibit MYD88 mutation,16 and CNS and testicu-
lar patients have a poor prognosis, with most cases being the 
activated B-cell type.   We previously reported that 59% of 
breast DLBCL cases have MYD88 L265P, leading to a poor 
prognosis,17 and only 6% of gastrointestinal DLBCL has 
MYD88 L265P.   Most cases are the ABC type, but the prog-
nosis is fair.18   These findings strongly suggest that MYD88 
L265P plays a key role in the lymphomagenesis of LPL and 
DLBCL, and is related to the prognosis.
CONCLUSION
CLL/SLL is a rare type of leukemia/lymphoma in Japan. 
Therefore, differential diagnosis is difficult for pathologists. 
Moreover, CLL cases in Japan are not uniform and some 
exhibit “atypical” features.   In this article, we did not 
describe atypical cases.   However, CLL/SLL should be dif-
ferentiated from other indolent types (small-sized lymphoma 
cells), including mantle cell lymphoma.   A precise diagnosis 
is needed to select the most effective therapy, and although 
the exact role of each molecule described in this article has 
not been fully clarified, the molecular pathogenesis will be 
clarified in the near future.   Newly developed drugs are 
expected to be used for lymphoma treatment.
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